► We present the case with the latest reported recurrence of low malignant potential ovarian tumor. ► Borderline ovarian tumors have the potential for delayed recurrence that is not always salvageable surgically. ► Optimization of surveillance strategies and lifelong follow up is required for these patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860968 | PMC |
http://dx.doi.org/10.1016/j.gynor.2012.08.002 | DOI Listing |
Sci Rep
January 2025
Department of Life Technologies, Division of Biotechnology, University of Turku, Medisiina D, 5th floor, Kiinamyllynkatu 10, 20520, Turku, Finland.
Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles.
View Article and Find Full Text PDFCancer Med
January 2025
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Background: Borderline ovarian tumors (BOTs) differ from ovarian carcinomas in their clinical presentation and behavior, yet their molecular characteristics remain poorly understood. This study aims to address this gap by integrating whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to compare BOTs with high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), and clear-cell carcinoma (CCC).
Objective: To elucidate the molecular features of BOTs and evaluate their similarities and differences in comparison to HGSC, EC, and CCC.
Eur J Obstet Gynecol Reprod Biol
January 2025
Medical Oncology Department, Marqués de Valdecilla University Hospital, IDIVAL, Cantabria, Spain.
Objectives: To assess the recurrence rate and quality of life (QOL) in women with a history of borderline ovarian tumours (BOTs) based on the type of surgery (conservative vs non-conservative) in Spain.
Study Design: A retrospective analysis was conducted of 85 women treated for BOTs between 2007 and 2023 at two hospitals. QOL questionnaires were administered face-to-face to eligible patients.
Cureus
December 2024
Obstetrics and Gynecology, Cape Fear Valley Health, Fayetteville, USA.
Pelvic masses in women can originate from both gynecological and non-gynecological sources, necessitating careful evaluation to ensure appropriate treatment. Gynecological masses can range from functional ovarian cysts and tubo-ovarian abscesses to malignant and benign tumors. This case report presents a mucinous borderline ovarian tumor (BOT), a rare type of ovarian neoplasm.
View Article and Find Full Text PDFAcad Radiol
January 2025
Department of Radiology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China (X.W., X.C., Y.C., S.C., M.W.). Electronic address:
Rationale And Objectives: To develop and validate a deep learning radiomics nomogram (DLRN) based on T2-weighted MRI to distinguish between borderline ovarian tumors (BOTs) and stage I epithelial ovarian cancer (EOC) preoperatively.
Materials And Methods: This retrospective multicenter study enrolled 279 patients from three centers, divided into a training set (n = 207) and an external test set (n = 72). The intra- and peritumoral radiomics analysis was employed to develop a combined radiomics model.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!